



OncoFOLLOW is a non-invasive personalised liquid biopsy test designed to monitor a patient's response to a treatment from circulating tumour DNA. Our OncoFOLLOW test will allow you to identify :



- Tumour recurrence
- Potential mechanisms of resistance
- New treatment options

WHY RUN A PERSONALISED ONCOFOLLOW TEST?


During the evolution of the disease, each metastatic clone evolves and alters its molecular genotype, making clinical decisions challenging. Having an easily accessible and minimally invasive way to determine and to follow the molecular makeup of a patient's tumour longitudinally is key to enable precision medicine. From a simple blood sample, our OncoFOLLOW test offers a unique personalisation of the assay based on the patient-specific tumour mutations previously identified by next-generation sequencing. The test allows the monitoring of the burden of the disease by significantly reducing the probability of getting false negative results, assesses the efficacy of current treatment and may identify new therapies of potential clinical benefit.

WHEN TO PERFORM ONCOFOLLOW ?

Although there are no fixed guidelines, based on our internal assessment, OncoFOLLOW should ideally be performed in the middle of the treatment and about two weeks after the last intake. The testing frequency of the subsequent OncoFOLLOW testing will depend on the treatment administered, the cancer type and the patient's anamnesis. Periodicity can be discussed with the treating oncologist on a case-by-case basis.

MATERIAL  **2 blood samples** (2 Streck tubes of 10 ml each) 

PERSONALISED LIQUID BIOPSY

LIQUID BIOPSY  **Next-generation sequencing**

- Each test is designed on the unique molecular signature of the tumour which has been defined through previous genomic sequencing performed on either a solid or a liquid biopsy.
- Each test targets up to 20 patient-specific mutations which are complemented by a **40-gene** core panel containing mutations (SNV, Indels and CNV) or resistance and sensitivity to targeted therapies. This personalised combination aims at monitoring a recurrence of the cancer and looking for additional treatment options.

INTEGRATED THERANOSTIC REPORT

- Liquid biopsy view
- Dynamic evolution of the personalised variants
- Reporting of new variant(s) associated with a treatment resistance and/or new therapeutical options
- Treatment options for targeted therapies
- Clinical trials availability



WHAT MAKES ONCOFOLLOW UNIQUE?

OncoDNA offers a personalised test based on a simple blood draw that combines the analysis of up to 20 patient-specific biomarkers with a core 40-gene panel to monitor the cancer evolution and identify new treatment options.



HOW LONG DOES IT TAKE TO GET THE TEST RESULTS?

Our accredited laboratories (ISO 15189, CLIA-CAP) start running the tests as soon as they receive the blood samples. The results are issued in our web-based platform OncoSHARE within **10 working days starting from the reception** of the liquid biopsy samples and the receipt of all clinical information and personalized primers synthesis required to launch the analysis process.

FOR WHOM IS ONCOFOLLOW TEST DESIGNED?

Our OncoFOLLOW test is designed for any adult suffering from a **metastatic solid cancer and whose solid or liquid biopsy has already been sequenced**.